This platform was built from metadata aggregated by the Chaire AgingUP! team from Université Paris Cité, using twenty years of academic research on health economics and health policy analysis. It combines large-scale public datasets, peer-reviewed research methods and advanced analytics to provide decision-makers with actionable insights on medicines, healthcare systems and market access. Originally developed within an academic environment, the platform translates rigorous research into practical tools designed to support evidence-based decision making. The underlying databases and analytical frameworks have been developed through collaborations with leading academic institutions and international organizations, and are continuously enriched through ongoing research activities. The objective of this research project is to explore the dynamics of the US pharmaceutical market through empirical analyzes. It builds on the following working paper: Rapp T., “Exploring Retail Acquisition Price Convergence After ANDA Market Entry in the United States, 2013–2026” (Université Paris Cité, LIRAES & Chaire AgingUP!; Sciences Po Paris, LIEPP).
Where the prices come from. Every price on this platform is a Drug Acquisition Cost: what retail / community pharmacies actually pay to buy a drug from wholesalers and manufacturers. It is surveyed monthly from pharmacy invoices and published by CMS — a real transaction price upstream of the patient, not a list price.
What this price is — and is not. The Drug Acquisition Cost is the retail pharmacy acquisition channel only: it excludes hospital / inpatient and 340B pricing, commercial / private-insurer negotiated prices, patient out-of-pocket cost, and manufacturer list price (WAC). Medicare Part D spending and Medicare coverage decisions are included as dedicated modules, but the acquisition cost itself is not a Medicare or net (post-rebate) price.
Where the volumes come from. Prescription and unit volumes are from Medicaid drug-utilization data (CMS), a large but partial slice of total US demand (Medicaid beneficiaries only). They show structure and trends, not the whole market.
The aggregated econometric base. The full-market econometric results (event study and price-convergence regressions) reproduce the author's peer-reviewed research: Rapp T., “Exploring Retail Acquisition Price Convergence After ANDA Market Entry in the United States, 2013–2026” (Université Paris Cité, LIRAES & Chaire AgingUP!; Sciences Po Paris, LIEPP).
Data sources mobilised. All public, all chained at the molecule level, from official US providers: the Food and Drug Administration (approvals, regulatory records, drug labels & safety) · the Centers for Medicare & Medicaid Services (retail & payer pricing, prescription utilization, coverage and transparency data) · the National Institutes of Health (clinical-trial registry) · an open scientific-literature index.